Biostar Pharmaceuticals (Biostar Pharmaceuticals) COGS-to-Revenue : 0.00 (As of Sep. 2017)

View and export this data going back to 2008. Start your Free Trial

What is Biostar Pharmaceuticals COGS-to-Revenue?

Biostar Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2017 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2017 was $0.00 Mil.

Biostar Pharmaceuticals's COGS to Revenue for the three months ended in Sep. 2017 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Biostar Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2017 was N/A%.

Biostar Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Biostar Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biostar Pharmaceuticals COGS-to-Revenue Chart

Biostar Pharmaceuticals Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

COGS-to-Revenue

Get a 7-Day Free Trial

0.39

0.51

0.59

0.62

Biostar Pharmaceuticals Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
COGS-to-Revenue	Get a 7-Day Free Trial															0.52	1.12	-	-	-

Biostar Pharmaceuticals COGS-to-Revenue Calculation

Biostar Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2016 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.469	/	2.384
	=	0.62

Biostar Pharmaceuticals's COGS to Revenue for the quarter that ended in Sep. 2017 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Biostar Pharmaceuticals (OTCPK:BSPM) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Biostar Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2017 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Biostar Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biostar Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biostar Pharmaceuticals (Biostar Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biostar Pharmaceuticals Inc (OTCPK:BSPM) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 588 Shiji Xi Avenue, Shaanxi Province, Xianyang, CHN, 712046

Website

http://www.biostarpharmaceuticals.com

Biostar Pharmaceuticals Inc through its subsidiaries involves in the development, manufacturing, and marketing of pharmaceutical products for a variety of diseases and conditions in the People's Republic of China where it generates most of its revenues. The company's products include Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (OTC) medicine for chronic hepatitis B. The current product line of the company also includes several other OTC products and approximately 15 prescription-based pharmaceuticals. Its products are derived from medicinal herbs that are either grown at its own facility or purchased from the suppliers.

Biostar Pharmaceuticals (Biostar Pharmaceuticals) Headlines

From GuruFocus

Biostar Pharmaceuticals Announces Receipt of Additional Delisting Determination Letter from Nasdaq

By Marketwired Marketwired • 08-23-2018

Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice

By PRNewswire PRNewswire • 04-23-2018